1. Home
  2. BMHL vs ALDX Comparison

BMHL vs ALDX Comparison

Compare BMHL & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BMHL

Bluemount Holdings Limited Class B Ordinary Shares

N/A

Current Price

$3.94

Market Cap

100.8M

Sector

N/A

ML Signal

N/A

Logo Aldeyra Therapeutics Inc.

ALDX

Aldeyra Therapeutics Inc.

HOLD

Current Price

$1.72

Market Cap

101.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMHL
ALDX
Founded
2016
2004
Country
Hong Kong
United States
Employees
9
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
100.8M
101.1M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
BMHL
ALDX
Price
$3.94
$1.72
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.50
AVG Volume (30 Days)
2.4K
1.1M
Earning Date
06-13-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
40.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$66.66
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.72
$1.07
52 Week High
$4.48
$6.18

Technical Indicators

Market Signals
Indicator
BMHL
ALDX
Relative Strength Index (RSI) 64.06 42.12
Support Level $3.25 $1.48
Resistance Level $4.20 $1.89
Average True Range (ATR) 0.15 0.10
MACD 0.05 0.08
Stochastic Oscillator 92.31 62.82

Price Performance

Historical Comparison
BMHL
ALDX

About BMHL Bluemount Holdings Limited Class B Ordinary Shares

Bluemount Holdings Ltd through its operating subsidiaries, it is a Hong Kong-based consulting and advisory and financial services provider, as well as trader of commodities such as luxury timepieces. The financial services includes underwriting and placing services, securities dealing and brokerage services, and asset management services. It provides comprehensive consulting and advisory services on business development strategies to its diverse clientele. Generally, the company provides consulting and advisory business for the following segments: Corporate Finance; and Strategic Communications.

About ALDX Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Share on Social Networks: